{
  "source": "PA-Notification-Vijoice.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 1388-4\nProgram Prior Authorization/Notification\nMedication Vijoice® (alpelisib)\nP&T Approval Date 6/2022, 6/2023, 6/2024, 6/2025\nEffective Date 9/1/2025\n1. Background:\nVijoice® (alpelisib) is a kinase inhibitor indicated for the treatment of adult and pediatric patients\n2 years of age and older with severe manifestations of PIK3CA-Related Overgrowth Spectrum\n(PROS) who require systemic therapy. This indication is approved under accelerated approval\nbased on response rate and duration of response. Continued approval for this indication may be\ncontingent upon verification and description of clinical benefit in a confirmatory trial(s).\n2. Coverage Criteria a:\nA. Initial Authorization\n1. Vijoice will be approved based on all of the following criteria:\na. Diagnosis of PIK3CA-Related Overgrowth Spectrum (PROS)\n-AND-\nb. Patient is 2 years of age or older\n-AND-\nc. Patient has severe manifestations of PROS requiring systemic therapy\nAuthorization will be issued for 12 months.\nB. Reauthorization\n1. Vijoice will be approved based upon the following criterion:\na. Documentation of positive clinical response to Vijoice therapy.\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n© 2025 UnitedHealthcare Services Inc.\n1\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n• Supply limits, Medical Necessity, and/or Step Therapy may be in place.\n4. References:\n1. Vijoice [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; April 2024.\n",
    "apeutic class.\n• Supply limits, Medical Necessity, and/or Step Therapy may be in place.\n4. References:\n1. Vijoice [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; April 2024.\nProgram Prior Authorization/Notification – Vijoice® (alpelisib)\nChange Control\n6/2022 New program.\n6/2023 Annual review. Added state mandate footnote. Updated references.\n6/2024 Annual review. Updated initial authorization to 12 months. Updated\nreferences.\n6/2025 Annual review without changes to coverage criteria.\n© 2025 UnitedHealthcare Services Inc.\n2"
  ]
}